Tuberc Respir Dis.
2022 Jan;85(1):98-99. 10.4046/trd.2021.0135.
Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline: Authors’ Reply
- Affiliations
-
- 1Department of Internal Medicine, Dongkang Medical Center, Ulsan, Republic of Korea
- 2Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea
- 3Pusan National University School of Medicine, Busan, Republic of Korea
- 4Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea
- KMID: 2523550
- DOI: http://doi.org/10.4046/trd.2021.0135
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Concurrent, Prolonged Use of Bedaquiline and Delamanid for Multidrug-Resistant Tuberculosis
- Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline
- Erratum: Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
- Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis
- Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
